+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Insomnia Treatment Market 2020-2026

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129695
Global Insomnia Treatment Market Size, Share & Trends Analysis Report by Type (Drugs (Antidepressant, Benzodiazepine, Nonbenzodiazepine, Melatonin Receptor Agonist, Orexin Antagonist, and Others), and Devices), and by Sales Channels (Prescription and Over-the-Counter (OTC)), and Forecast 2020-2026
The global insomnia treatment market is projected to grow significantly during the forecast period. The key aspects that drive the growth of the market include the increased levels of stress among the peoples, increased cases of insomnia, and rising awareness regarding the availability of treatment of insomnia. Moreover, the launch of various drugs and the availability of multiple generics is anticipated to enhance the growth of the market. For instance, in December 2019, the US FDA approved the Eisai’s drug named Lemborexant, a novel Orexin Receptor Antagonist (ORA) for the treatment of insomnia.

The global insomnia treatment market is segmented on the basis of type and sales channels. Based on the type, the market is segmented into drugs and devices. The drugs segment is projected to hold a significant share in the market. Drugs segment is further divided into antidepressants, benzodiazepine, nonbenzodiazepine, melatonin receptor agonist, orexin antagonist, and others. Based on the sales channels, the market is segmented as prescription, and over-the-counter (OTC). The prescription segment is likely to contribute significantly to the market growth during the forecast period.

Geographically, the study of the global insomnia treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global insomnia treatment market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Further, Arena Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others are some of the prominent players operating in the global insomnia treatment market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market.

Research Methodology

The market study of the global insomnia treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for insomnia treatment market players, drug manufacturing companies, investment companies, industry associations & experts, research institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Insomnia Treatment Market Research and Analysis by Type
2. Global Insomnia Treatment Market Research and Analysis by Sales Channel

The Report covers:
  • Comprehensive research methodology of the global insomnia treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global insomnia treatment market.
  • Insights about market determinants which are stimulating the global insomnia treatment market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.2. Sanofi SA Overview Financial Analysis SWOT Analysis Recent Developments
3.2.3. Merck & Co. Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.4. Takeda Pharmaceuticals Co. Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.5. Boehringer Ingelheim International GmbH Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Insomnia Treatment Market by Type
5.1.1. Drugs Antidepressants Benzodiazepine Nonbenzodiazepine Melatonin Receptor Agonist Orexin Antagonist Others
5.1.2. Devices
5.2. Global Insomnia Treatment Market by Sales Channels
5.2.1. Prescription
5.2.2. Over-the-Counter (OTC)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Arena Pharmaceuticals, Inc.
7.2. Boehringer Ingelheim International GmbH
7.3. Eisai Co. Ltd.
7.4. Electromedical Products International Inc.
7.5. Eli Lilly and Co.
7.6. GlaxoSmithKline Plc
7.7. Mallinckrodt LLC
7.8. Merck & Co. Inc.
7.9. Mylan N.V.
7.10. Natrol, LLC
7.11. Paratek Pharmaceuticals Inc.
7.12. Pfizer Inc.
7.13. Sanofi SA
7.14. Sumitomo Dainippon Pharma Co. Ltd.
7.15. Takeda Pharmaceutical Co. Ltd.
7.16. Teva Pharmaceutical Industries Ltd.
7.17. Vanda Pharmaceuticals Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Arena Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co. Ltd.
  • Electromedical Products International Inc.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Mallinckrodt LLC
  • Merck & Co. Inc.
  • Mylan N.V.
  • Natrol, LLC
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vanda Pharmaceuticals Inc.